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What Women and Their Physicians Need to Know About the 
UKCTOCS Study and Ovarian Cancer Screening
Ovarian Cancer Research Fund Alliance and Banbury Conference Writing Group
In February 2016, the Ovarian Cancer Research Fund Alliance convened a group of 25 
scientists, clinicians, and advocates to meet at the Banbury Center, Cold Spring Harbor 
Laboratory, to discuss the recent results from the United Kingdom Collaborative Trial of 
Ovarian Cancer Screening (UKCTOCS) and implications for clinical practice and public 
health.
Ovarian cancer is a relatively rare type of cancer that affects approximately 1.5% of U.S. 
women during their lifetime, but it is the fifth most common cause of cancer death among 
women.1 The five-year survival rate is only about 45% because most women present with 
advanced-stage disease.1 There has not been an accepted early detection test because of a 
lack of evidence that any screening approach reduces death from ovarian cancer. At the time 
of the conference, no organization had issued a guideline recommending screening for 
ovarian cancer in women not at increased risk.
The current recommendations against screening for ovarian cancer are based on the large 
U.S. prospective randomized Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer 
Screening Trial.2 The PLCO trial demonstrated that an annual cancer antigen (CA) 125 
measurement (using a fixed cutoff value for a positive test result) and ultrasonography were 
not associated with a reduction in mortality from ovarian cancer. Furthermore, screening was 
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associated with significant harms resulting from surgeries that were triggered by false-
positive findings.
In December 2015, the results of the UKCTOCS trial were reported in The Lancet.3 This 
landmark study included approximately 200,000 healthy postmenopausal women, of whom 
one-half were randomized to no screening, one-fourth were randomized to receive annual 
pelvic ultrasonography, and one-fourth were randomized to multimodal screening (MMS). 
In contrast to the PLCO approach, MMS involves a risk of ovarian cancer algorithm 
(ROCA) that assigns a level of risk based on an individual woman’s CA 125 levels and 
changes over time combined with her age and known risk factors for ovarian cancer. Based 
on these findings, further CA 125 testing and ultrasonography may be required.
The primary analysis suggested a nonsignificant mortality reduction over years 0 to 14 of 
15% (95% confidence interval, −3 to 30; P = .10) in the MMS arm vs. the usual care arm. 
However, the reduction in mortality was not constant over time, appearing only after seven 
to 10 years of screening. Compared with annual, fixed-cutoff CA 125 levels and 
ultrasonography, as were studied in the PLCO trial, the MMS algorithm was more sensitive 
and led to fewer unnecessary surgeries. The UKCTOCS trial demonstrated a stage shift in 
which more cases were diagnosed at an early stage with the MMS approach (40%) 
compared with women in the nonscreened (usual care) group (26%). There was no stage 
shift observed for the group receiving ultrasonography alone. Additional exploratory 
analysis suggested even more encouraging, though as yet inconclusive, evidence of the 
potential for a greater mortality reduction in the MMS group.
As stated in The Lancet UKCTOCS paper, “further follow-up is needed before firm 
conclusions can be reached on the efficacy and cost-effectiveness of ovarian cancer 
screening.”3 The consensus of the Banbury group is in accord with the published 
conclusions of the UKCTOCS trial: It is premature to recommend MMS for the early 
detection of ovarian cancer at this time. Although women and health care professionals may 
look to these findings as finally providing a strategy for successful screening for ovarian 
cancer, the study investigators and participants at this meeting believe that screening policy 
requires a sound scientific foundation, which we currently do not have. The study results 
will be reanalyzed using the additional data in three years, and firmer conclusions may 
emerge. This analysis will be eagerly awaited, because there will not be a similarly powered 
ovarian cancer screening study in the foreseeable future. We commend the trial investigators 
for undertaking and completing this ambitious trial, and thank the women whose 
participation made it possible.
The ROCA, a component of the MMS strategy evaluated in the UKCTOCS trial, is already 
commercially available. Although no organization recommends ovarian cancer screening in 
average-risk women, some women may wish to undergo periodic screening for ovarian 
cancer with CA 125 testing; therefore, health care professionals must advise women 
regarding the potential benefits and risks as we understand them now. Given the gaps in the 
evidence, the majority of Banbury participants were uncomfortable with direct-to-consumer 
advertising of an ovarian cancer screening test at this time.
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